The nontargeted antiobesity medications (AOM), such as naltrexone-bupropion and glucagon-like peptide-1 (GLP-1) receptor agonists, have been approved for obesity treatment in general, whereas the targeted pharmacotherapeutical agent, setmelanotide, has only been approved for specific genetic obesity disorders. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.